**Appendix. Detailed information of the questionnaire**

|  |  |  |
| --- | --- | --- |
| Questions | No  (n=1,021) | % |
| 1.What is your gender？ | | |
| Male | 588 | 57.6 |
| Female | 433 | 42.4 |
| 2.What is your age? | | |
| 20-31 | 23 | 2.3 |
| 31-40 | 198 | 19.4 |
| 41-50 | 411 | 40.3 |
| >50 | 389 | 38.1 |
| 3.Where do you work? | | |
| East | 321 | 31.4 |
| Central | 351 | 34.4 |
| West | 255 | 25.0 |
| Northeast | 94 | 9.2 |
| 4. How long have you been working? | | |
| 1-5 years | 35 | 3.4 |
| 6-15 years | 179 | 17.5 |
| 16-25 years | 322 | 31.5 |
| >25 years | 485 | 47.5 |
| 5.What is your title? | | |
| Resident | 27 | 2.6 |
| Attending physician | 136 | 13.3 |
| Deputy chief physician | 356 | 34.9 |
| Chief physician | 502 | 49.2 |
| 6. Which department are you in? | | |
| Hepatology Department | 367 | 36.0 |
| Infection Department | 397 | 38.9 |
| Gastroenterology Department | 178 | 17.4 |
| Oncology Department | 14 | 1.4 |
| Interventional Radiotherapy Department | 2 | 0.2 |
| Others | 37 | 3.6 |
| 7.What is the level of your hospital? | | |
| Secondary and lower hospital | 265 | 26.0 |
| Tertiary hospital | 185 | 18.1 |
| Tertiary first-class hospital | 571 | 55.9 |
| 8. What is the type of your hospital? | | |
| Specialist hospital | 229 | 22.4 |
| General hospital | 792 | 77.6 |
| 9. Do you think it is necessary to prescribe serum markers such as alpha-fetoprotein and abdominal imaging examinations for patients with liver disease during regular outpatient follow-ups? | | |
| Yes | 1017 | 99.6 |
| No | 4 | 0.4 |
| 10. Is your hospital equipped to determine the nature of the liver masses? | | |
| Yes | 981 | 96.1 |
| No | 40 | 3.9 |
| 11. What is your recommendation when the diagnosis is vague? | | |
| Local hospitals | 153 | 15.0 |
| Provincial capital hospitals | 462 | 45.3 |
| Hospitals in Beijing and Shanghai | 406 | 39.8 |
| 12. Is the method of diagnosis enough? | | |
| Yes | 513 | 50.2 |
| No | 508 | 49.8 |
| 13. What is the percentage of first diagnosis? | | |
| 0-20% | 540 | 52.9 |
| 20-40% | 291 | 28.5 |
| 40-60% | 112 | 11.0 |
| >60% | 78 | 7.6 |
| 14. What is the percentage of advanced stage cancer？ | | |
| 0-20% | 95 | 9.3 |
| 20-40% | 205 | 20.1 |
| 40-60% | 386 | 37.8 |
| >60% | 335 | 32.8 |
| 15. Is the pathological diagnosis important? | | |
| Yes | 519 | 50.8 |
| No | 502 | 49.2 |
| 16. If patients with hepatitis B-related liver cancer are positive for the virus, do they need immediate antiviral treatment? | | |
| Yes | 1004 | 98.3 |
| No | 17 | 1.7 |
| 17. If patients with hepatitis C-related liver cancer are positive for the virus, do they need immediate antiviral treatment? | | |
| Yes | 982 | 96.2 |
| No | 39 | 3.8 |
| 18. Will you actively help a patient with NASH through lifestyle changes, exercise, weight loss and other measures to reduce the possibility of subsequent liver cirrhosis and liver cancer? | | |
| Yes | 1010 | 98.9 |
| No | 11 | 1.1 |
| 19. Who will make the final decisions on the treatment? |  |  |
| Doctors | 141 | 13.8 |
| Patients | 242 | 23.7 |
| Patients’ family | 638 | 62.5 |
| 20. Do you support telling the truth of the patients’ conditions? |  |  |
| Yes | 632 | 61.9 |
| No | 389 | 38.1 |
| 21. What’s your preferred treatment regimens? |  |  |
| Targeted therapy | 114 | 11.2 |
| Immunotherapy | 12 | 1.2 |
| Target therapy & Immunotherapy | 871 | 85.3 |
| Chemotherapy | 24 | 2.4 |
| 22. What’s your preferred targeted drugs? |  |  |
| Sorafenib | 572 | 56.0 |
| Lenvatinib | 344 | 33.7 |
| Rigorfenib | 26 | 2.6 |
| Apatinib | 70 | 6.9 |
| Cabotinib | 9 | 0.9 |
| 23. How do you deal with adverse effects of targeted therapy? |  |  |
| Keeping the dosage and frequency | 356 | 34.9 |
| Reducing the dosage | 533 | 52.2 |
| Interrupted medication on weekends | 48 | 4.7 |
| Take medicine every other day | 84 | 8.2 |
| 24. What’s your preferred immunotherapy drugs? |  |  |
| PD-1 | 773 | 75.7 |
| PD-L1 | 210 | 20.6 |
| CTLA4 | 38 | 3.72 |
| 25. What’s your major drug source? |  |  |
| Imported | 338 | 33.1 |
| Domestic | 154 | 15.1 |
| Available | 529 | 51.8 |
| 26. What’s your major considerations for prescribing? |  |  |
| Insurance | 303 | 29.7 |
| Effectiveness | 494 | 48.4 |
| Cost | 57 | 5.6 |
| Availability | 167 | 16.4 |
| 27. Do you advocate traditional Chinese medicine? |  |  |
| Yes | 634 | 62.1 |
| No | 387 | 37.9 |
| 28. Are drugs sufficient? |  |  |
| Yes | 250 | 24.5 |
| No | 771 | 75.5 |
| 29. Is the price of medication acceptable? | | |
| Yes | 287 | 28.1 |
| No | 734 | 71.9 |
| 30. Is the treatment satisfactory? | | |
| Yes | 239 | 23.4 |
| No | 782 | 76.6 |
| 31. Which of the following treatment models for liver cancer do you approve? | | |
| Complete cure | 570 | 55.8 |
| Long-term treatment | 913 | 89.4 |
| Minimize the suffering of patients and improved the quality of lives | 908 | 88.9 |
| Not to implement painful and risky treatment | 119 | 11.7 |
| 32. What do patients with liver cancer need? | | |
| Psychological counseling | 953 | 93.3 |
| Improvement in the quality of life | 958 | 93.8 |
| Relief of economic burden | 952 | 93.24 |
| Promoted early diagnosis rate | 971 | 95.1 |
| More new medications available | 916 | 89.7 |
| 33. How would you like to get access to the updated knowledge on the progress of liver cancer diagnosis and treatment? | | |
| Participating in academic conferences | 1000 | 97.9 |
| Accessing journal literature | 922 | 90.3 |
| Attending video lectures on professional websites | 968 | 94.8 |
| Learning the official policy | 548 | 53.7 |